Novel myostatin-specific antibody enhances muscle strength in muscle disease models

Abstract Myostatin, a member of the transforming growth factor-? superfamily, is an attractive target for muscle disease therapy because its role as negative regulator and strength. Here, we describe novel antibody therapeutic approach that maximizes potential myostatin-targeted therapy. We generated antibody, GYM329, specifically binds latent form myostatin inhibits activation. Additionally, via “sweeping technology”, GYM329 reduces or “sweeps” in plasma. Compared with conventional anti-myostatin agents, surrogate exhibit superior strength-improvement effects three different mouse models. also demonstrate efficacy due to specificity sweeping capability. Furthermore, show increases mass normal cynomolgus monkeys without any obvious toxicity. Our findings indicate improve strength patients muscular disorders.